Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Randomized, Observer-Blinded, Active-Controlled, Dose, Escalation Multicenter Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Participants 50 Years of Age and Over

NCT06569823 is registered in ClinicalTrials.gov with Dynavax Technologies Corporation as lead sponsor.

NCT NCT06569823
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06569823 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Randomized, Observer-Blinded, Active-Controlled, Dose, Escalation Multicenter Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Participants 50 Years of Age and Over
Lead sponsor
Dynavax Technologies Corporation
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
June 17, 2024
Completion date
November 30, 2031
Enrollment
764 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

herpes zoster, shingles, vaccine-preventable diseases